SureTrader Advertisement PRTC
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 5/30/2016 11:53:43 PM - Followers: 759 - Board type: Free - Posts Today: 0

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: dianne@elitepharma.com

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ELTP News: Current Report Filing (8-k) 05/04/2016 10:36:36 AM
ELTP News: Initial Statement of Beneficial Ownership (3) 05/04/2016 10:21:25 AM
ELTP News: Statement of Changes in Beneficial Ownership (4) 05/03/2016 11:52:20 AM
ELTP News: Initial Statement of Beneficial Ownership (3) 04/25/2016 12:43:52 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 04/15/2016 03:14:26 PM
PostSubject
#200119  Sticky Note Dear WeeZuhl, WeeZuhl 05/15/16 10:56:35 AM
#198430  Sticky Note Kempharm fails to acquire ADF label. WeeZuhl 05/05/16 09:37:53 PM
#193807  Sticky Note ELITE PHARMACEUTICAL positioned to capitalize on opiod crisis NASDAQ2020 04/11/16 04:41:02 PM
#189575  Sticky Note 4-REASONS-ELTP-is-in-the-Midst-of-the-Perfect-Storm:-A-GREAT-BUY-NOW: Couch 03/18/16 07:41:32 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#202528   PDUFA date 30 trading sessions left Dr_Thorfin 05/30/16 11:53:43 PM
#202527   Agree i like whats ahead of us Padin 05/30/16 11:28:45 PM
#202526   Jimmy I love the way you are thinking. Gman24 05/30/16 09:29:18 PM
#202525   Looking forward to it also. Great times ahead Gman24 05/30/16 09:23:07 PM
#202524   Correct, should be interesting reading when the ADCOM rollin2nyte 05/30/16 09:09:12 PM
#202523   ELTP Contest- If you want to add, copy heidibrown 05/30/16 08:52:08 PM
#202522   hondobud put me down for the following.... Jimmy Joe 05/30/16 08:19:23 PM
#202521   Lasers question... will Elite come out with a Jimmy Joe 05/30/16 08:13:27 PM
#202520   Is that the best you have? "So what?" Sheeez! Jimmy Joe 05/30/16 08:08:18 PM
#202518   I'm sure Rollin said that in jest... He Gman24 05/30/16 07:39:52 PM
#202517   Article: jour_trader 05/30/16 07:38:08 PM
#202516   We want Pfizer's ALO-02 (ER ADT Oxy / mrwrn2010 05/30/16 07:35:36 PM
#202515   rollin, or others, why would bad news for brownsfan407 05/30/16 07:32:40 PM
#202514   ELTP Contest- If you want to add, copy Chasing 05/30/16 07:12:53 PM
#202513   Thanx, I would love to listen to it. NASDAQ2020 05/30/16 07:03:17 PM
#202512   investorshub.advfn.com/uimage/uploads/2016/5/29/[qntkadf.png heidibrown 05/30/16 06:48:16 PM
#202511   the money that has been promised for a decade?? dr_lowenstein 05/30/16 05:26:52 PM
#202510   yeah..where's couch and lasers..? luvwetscent 05/30/16 04:54:01 PM
#202509   ELTP Contest- If you want to add, copy fivebronn 05/30/16 04:47:01 PM
#202508   Nas, as you can see below the recording KravMD 05/30/16 04:23:23 PM
#202507   So money, that's what. mrwrn2010 05/30/16 04:17:35 PM
#202506   ELTP Contest- If you want to add, copy hondobud 05/30/16 04:15:06 PM
#202505   We still have members not cheking in steve9465 05/30/16 04:01:07 PM
#202504   $ELTP $multi-Billion product ADFs!!!! lasers 05/30/16 03:51:00 PM
#202503   Yes, of course Mazeppa, when Naz get's approval sharkey1 05/30/16 03:38:50 PM
#202502   Add em up. NASDAQ2020 05/30/16 03:23:13 PM
#202499   ELTP Contest hondobud 05/30/16 03:11:41 PM
#202498   Most definitely. $ELTP NH setting the bar high lasers 05/30/16 03:10:15 PM
#202497   Doc is there a recording of the webinar NASDAQ2020 05/30/16 03:08:41 PM
#202496   PHARMAS HUNGRY FOR M & A's Mazeppa 05/30/16 02:57:23 PM
#202495   That's a multi-billion dollar pipeline if I've ever NASDAQ2020 05/30/16 02:54:43 PM
#202494   Elite Pharma is days away from having a NASDAQ2020 05/30/16 02:50:53 PM
#202493   Looking forward to $ELTP having IR, 12Hr ER, lasers 05/30/16 02:36:37 PM
#202491   so what? dr_lowenstein 05/30/16 01:26:07 PM
#202490   $ELTP SequestOx FDA approval on its way any lasers 05/30/16 01:09:08 PM
#202487   Wow. All this and we trade Je3232 05/30/16 12:55:44 PM
#202486   OMG, now medical advice!!! Different drugs, different role dr_lowenstein 05/30/16 12:28:07 PM
#202483   With the FDA its always an if. The Jimmy Joe 05/30/16 12:14:24 PM
#202481   Titan Probuphine is a CIII Buprenorphine implant to lasers 05/30/16 12:01:56 PM
#202480   Why does the world spin around? Jimmy Joe 05/30/16 11:54:53 AM
#202479   No it is a opioid addiction treatment drug. Moose45 05/30/16 11:52:21 AM
#202478  Restored total bullshit, but thanks Dr PeteRose MLB 05/30/16 11:38:01 AM
#202476   TTNP had a heavy selling date on May COO2002COO 05/30/16 11:11:40 AM
#202475   TTNP Titan Pharma had an FDA target action Moose45 05/30/16 10:52:28 AM
#202474   But why does no one else except a Je3232 05/30/16 10:31:21 AM
#202473   Don't forget there are 16 more ADFs to NASDAQ2020 05/30/16 10:29:47 AM
#202472   Yes. Shareholders must be patient however after approval lasers 05/30/16 10:23:08 AM
#202470   This is what I hope for. I tenor15824 05/30/16 09:40:30 AM
#202469   They also are producing 8 generics whoops, scam stockboy 05/30/16 07:48:05 AM
#202468   Amazing how the BS I've been hearing since Couch 05/30/16 07:32:22 AM
PostSubject